Don't want to miss the best from Business Standard?
Wednesday, December 03, 2025 | 10:16 PM ISTहिंदी में पढें
DRL semaglutide ruling may set precedent for generic makers: Experts
Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases
 "Dr Reddy's Laboratories, DRL downsizing, DRL employee cost cuts, Dr Reddy's Laboratories layoffs, pharma layoffs, DRL Revlimid sales, DRL FY24 report, DRL digital therapeutics, DRL nutraceuticals, DRL employee count, DRL Ebitda margin, Nirmal Bang DR")
premium
This comes on the heels of another Delhi HC ruling that had allowed Hyderabad based Natco Pharma to launch a generic version of Roche’s spinal muscle atrophy (SMA) drug Risdiplam, marketed as Evrysdi.
The Delhi High Court’s (HC’s) ruling allowing drugmaker Dr Reddy's Laboratories (DRL) to manufacture and export its generic version of semaglutide in non-protected markets of patent holder Novo Nordisk may serve as a potential precedent for other similar cases, according to legal experts.
While the detailed order had not been uploaded at the time of going to print, lawyers told Business Standard that the Delhi HC ruling allows DRL to make and export semaglutide where Novo Nordisk does not have patent protection, but blocks sales in India until the patent remains valid, that is, until March 2026.
Both DRL and
